Packaging | May 14, 2024
Coveris invests over €8 million in production capacity
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Lupin updates on shipment of Mirabegron ER Tablets
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
The proposed facility is expected to be operational around January, 2027
Subscribe To Our Newsletter & Stay Updated
